Modified-Release (MR) drug delivery can also have commercial benefits and is prevalent as part of product life-cycle management (LCM). Modest reformulation of an already approved drug from an IR to MR format allows both line and patent extension opportunities and continued market exclusivity.
Have a question about your poorly soluble molecule? Ask a member of our team about our capabilities for drug product formulation, clinical or commercial manufacturing to keep your drug program on-track.
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewVP, Global Commercial and Scientific Consulting - Drug Product
Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...
About AsmaSenior Director, Product Development
Robert Cornog has over 26 years of experience in product development and process design. Across a broad range of dosage forms and ...
About RobertSenior Director, Integrated Development
Brad Rowe joined the organization in 2005 and is based from our Philadelphia, PA sites in Garnet Valley and Boothwyn. He joined QS...
About Brad